StockNews.com initiated coverage on shares of NantHealth (NASDAQ:NH – Get Rating) in a report issued on Thursday morning. The firm issued a hold rating on the stock.

NantHealth Stock Performance

Shares of NH stock opened at $1.77 on Thursday. The stock has a market cap of $13.64 million, a PE ratio of -0.23 and a beta of 1.82. NantHealth has a 1 year low of $1.57 and a 1 year high of $11.85. The stock has a fifty day moving average price of $2.71 and a 200 day moving average price of $1.84.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in NH. Goldman Sachs Group Inc. acquired a new stake in NantHealth during the second quarter worth approximately $36,000. Millennium Management LLC acquired a new stake in shares of NantHealth during the second quarter worth $110,000. Finally, Atria Wealth Solutions Inc. boosted its holdings in shares of NantHealth by 117.7% during the second quarter. Atria Wealth Solutions Inc. now owns 491,942 shares of the company's stock worth $205,000 after purchasing an additional 265,949 shares during the last quarter. Institutional investors and hedge funds own 4.50% of the company's stock.

About NantHealth

(Get Rating)

NantHealth, Inc is an evidence-based, personalized healthcare company, which engages in the provision of treatment for critical diseases such as cancer. The firm empowers treatment decisions, improves patient outcomes, validates treatment options, enables high-quality care, lowers costs, ensures appropriate reimbursement, and streamlines implementation and deployment.

Read More

• Get a free copy of the StockNews.com research report on NantHealth (NH)
• MarketBeat Week in Review – 4/3 – 4/7
• Costco Sales Disappoint, Markets Are Missing This Upside Driver
• First Republic Bank Is A Speculative Play, Here's Why
• The WD-40 Company Bottoms With Reversal In Sight
• 3 Low-Cost Stock ETFs That Are Crushing It This Year

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.